RRX-001 is a Small Molecule owned by EpicentRx, and is involved in 12 clinical trials, of which 7 were completed, 2 are ongoing, and 3 are planned.
RRX-001 acts as CD47 inhibitors. CD47 levels are increased on the surface of cancer cells which show enhanced proliferation and survival. CD47 serves as a counter-receptor for SIRP alpha in recognition of self by the innate immune system. CD47 blockade control tumor growth by inhibiting thrombospondin-1 signaling or by preventing inhibitory SIRP alpha signaling in tumor-associated macrophages. The drug candidates exhibit therapeutic intervention by inhibiting CD47 or its ligand THBS1/thrombospondin 1.
The revenue for RRX-001 is expected to reach a total of $764m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the RRX-001 NPV Report.
RRX-001 is under development for the treatment of advanced solid tumors, metastatic colorectal cancer, brain metastases, small-cell lung cancer, Parkinson's disease, relapsed and refractory multiple myeloma, non-small cell lung cancer, radiation induced oral mucositis, small cell lung cancer, epithelial ovarian cancer, high grade neuroendocrine tumors, lymphoma, cerebral malaria, newly diagnosed high-grade glioma, including anaplastic glioma, glioblastoma, metastatic castration resistant neuroendocrine prostate cancer (NEPC), gliosarcoma, liver cancer, acute radiation syndrome, inflammation and recurrent or progressive malignant solid and central nervous system tumors. It is administered through intravenous, subcutaneous route and as a hepatic artery infusion. It is a prototypic dinitroazetidine molecule. The drug candidate has dual mode of action by acting as antivascular and anti-tumor agent. It acts by targetting CD47-SIRP alpha.
It was also under development for advanced cholangiocarcinoma, elapsed Multiple myeloma,cerebral (fatal) malaria, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, refractory multiple myeloma and lymphoma . The drug candidate is being developed based on CyNRGY platform.
SciClone Pharmaceuticals Holdings Overview
SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.
Quick View – RRX-001
|Highest Development Stage|